Results 21 to 30 of about 54,977 (304)

Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma

open access: yesCancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients with PDAC, but the correlations have been ...
Tianxing Zhou   +11 more
doaj   +1 more source

DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination

open access: yesJournal of Extracellular Vesicles, 2020
Early dissemination is a unique characteristic and a detrimental process of pancreatic ductal adenocarcinoma (PDAC); however, the underlying mechanism remains largely unknown.
Chu-An Wang   +10 more
doaj   +1 more source

Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma

open access: yesInternational Journal of Hyperthermia, 2021
Purpose This study aimed to compare the survival benefits between high-intensity focused ultrasound (HIFU) combined with chemotherapy and chemotherapy alone in patients with unresectable pancreatic ductal adenocarcinoma (PDAC).
Jing Guo   +4 more
doaj   +1 more source

Opioid analgesia in PDAC

open access: yes, 2023
Dataset of PDAC patients (in rows) including survival, histological, analgetic and molecular data (in columns)
Josef Srovnal (5190059)
core   +1 more source

Metabolism remodeling in pancreatic ductal adenocarcinoma

open access: yesCell Stress, 2019
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an ...
Jin-Tao Li   +3 more
doaj   +1 more source

Loss of FGFR4 promotes the malignant phenotype of PDAC [PDF]

open access: yes, 2022
Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours.
Bria, Emilio
core   +3 more sources

Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids

open access: yesInternational Journal of Nanomedicine, 2021
Julian Palzer,1,2 Benedikt Mues,2 Richard Goerg,1,2 Merel Aberle,3 Sander S Rensen,3 Steven WM Olde Damink,1,3 Rianne DW Vaes,3 Thorsten Cramer,1,3 Thomas Schmitz-Rode,2 Ulf P Neumann,1,3 Ioana Slabu,2 Anjali A Roeth1,3 1Department of General, Visceral ...
Palzer J   +11 more
doaj  

New Biomarker Identified for PDAC [PDF]

open access: yesCancer Discovery, 2017
Abstract A new study suggests that the protein THBS2 could lead to early detection of pancreatic ductal adenocarcinoma. By testing for THBS2 and another marker, CA19-9, researchers identified blood samples from patients with the disease with 98% specificity and 87% sensitivity.
openaire   +2 more sources

Targeting Pancreatic Ductal Adenocarcinoma (PDAC) [PDF]

open access: yesCellular Physiology and Biochemistry, 2020
Pancreatic cancers are among the most ominous, and among the most studied. Their complexities have provided ample material for a huge investigative effort, which is briefly surveyed in this review. Eradication by surgery has proven extremely difficult, and a successful chemotherapeutic approach is desperately needed.
Sofia Parrasia   +6 more
openaire   +5 more sources

Elevated microRNA expression could be diagnostic biomarker for PDAC

open access: yes, 2020
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year survival rate. PDAC is the most lethal malignancy worldwide and hence the molecular mechanisms, which are linked to the aggressive features, should be ...
Uysal Onganer, P.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy